Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 1Breast 1

Conditions

Neutropenia 1Chemotherapy-Induced Febrile Neutropenia 1Breast Neoplasms 1

Interventions

pegfilgrastim 22Filgrastim 11Cyclophosphamide 7Docetaxel 6eflapegrastim 4pegylated granulocyte colony-stimulating factor 3Vancomycin 2Itraconazole 2Granulocyte Colony-Stimulating Factor 2Fluorouracil 2Doxorubicin 2posaconazole 1ceftobiprole medocaril 1angiotensin I (1-7) 1Teicoplanin 1Sodium Chloride 1Oxaliplatin 1N,N'-bis(pyridoxal-5-phosphate)ethylenediamine-N,N'-diacetic acid 1Methotrexate 1Maxy G34 1Mannose-Binding Lectin 1MYL-1401H 1Leucovorin 1Fluconazole 1EC regimen 1Diet, High-Fat 1Cefepime 1Bevacizumab 1Amphotericin B 11-palmitoyl-2-linoleoyl-3-acetyl-rac glycerol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Neutropenia × MYL-1401H × Clear all
NCT02467868 2022-02-14

Efficacy and Safety Study With MYL-1401H and Neulasta

Viatris Inc.

Phase 3 Completed
193 enrolled
BreastClassical hematology

Breast Neoplasms, Neutropenia, Chemotherapy-Induced Febrile Neutropenia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡